Ted Wun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/662028/publications.pdf

Version: 2024-02-01

217 papers	8,422 citations	44069 48 h-index	51608 86 g-index
219 all docs	219 docs citations	219 times ranked	9013 citing authors

#	Article	IF	Citations
1	Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment. Journal of Clinical Oncology, 2001, 19, 1728-1733.	1.6	522
2	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 720-728.	27.0	520
3	Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival. Journal of Clinical Oncology, 2006, 24, 1112-1118.	1.6	325
4	Cocoa inhibits platelet activation and function. American Journal of Clinical Nutrition, 2000, 72, 30-35.	4.7	319
5	The incidence of venous thromboembolism among patients with primary lung cancer. Journal of Thrombosis and Haemostasis, 2008, 6, 601-608.	3.8	247
6	Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. Journal of Neurosurgery, 2007, 106, 601-608.	1.6	236
7	Epidemiology of cancer-related venous thromboembolism. Best Practice and Research in Clinical Haematology, 2009, 22, 9-23.	1.7	193
8	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	1.4	178
9	Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood, 2013, 121, 4782-4790.	1.4	174
10	Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2099.	7.4	173
11	The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thrombosis Research, 2002, 106, 191-197.	1.7	169
12	Cocoa and Wine Polyphenols Modulate Platelet Activation and Function. Journal of Nutrition, 2000, 130, 2120S-2126S.	2.9	155
13	Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors. Cancer Investigation, 2009, 27, 63-74.	1.3	150
14	Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood, 2009, 113, 3911-3917.	1.4	141
15	Venous thromboembolism in ovarian cancer. Gynecologic Oncology, 2007, 105, 784-790.	1.4	136
16	Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. Translational Research, 1997, 129, 507-516.	2.3	135
17	Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer, 2003, 98, 1514-1520.	4.1	135
18	Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical Trials. Journal of Clinical Oncology, 2005, 23, 9282-9289.	1.6	123

#	Article	IF	Citations
19	Platelet activation in patients with sickle cell disease. British Journal of Haematology, 1998, 100, 741-749.	2.5	117
20	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight, 2019, 4, .	5.0	110
21	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, 2017, 151, 89-95.	1.7	109
22	Increased risk of leukemia among sickle cell disease patients in California. Blood, 2017, 130, 1597-1599.	1.4	95
23	Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. American Journal of Medicine, 1999, 107, 573-579.	1.5	92
24	Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease*. International Journal of Laboratory Hematology, 2002, 24, 81-88.	0.2	91
25	Positron Emission Tomography and Improved Survival in Patients With Lung Cancer<subtitle>The Will Rogers Phenomenon Revisited</subtitle>. Archives of Internal Medicine, 2008, 168, 1541.	3.8	90
26	Acetaminophen and diphenhydramine as premedication for platelet transfusions: A prospective randomized double-blind placebo-controlled trial. American Journal of Hematology, 2002, 70, 191-194.	4.1	88
27	Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood, 2002, 99, 3999-4005.	1.4	87
28	High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody. Clinical Cancer Research, 2005, 11, 5920-5927.	7.0	87
29	Increased incidence of <scp>VTE</scp> in sickle cell disease patients: risk factors, recurrence and impact on mortality. British Journal of Haematology, 2017, 178, 319-326.	2.5	87
30	Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leukemia Research, 2004, 28, 179-190.	0.8	85
31	Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow. Blood, 2017, 130, 2101-2110.	1.4	69
32	High Variation Between Hospitals in Vena Cava Filter Use for Venous Thromboembolism. JAMA Internal Medicine, 2013, 173, 506.	5.1	68
33	Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis. Lung Cancer, 2014, 85, 264-269.	2.0	68
34	Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism. Circulation, 2016, 133, 2018-2029.	1.6	68
35	The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update. Seminars in Thrombosis and Hemostasis, 2019, 45, 321-325.	2.7	67
36	Inflammatory potential of neutrophils detected in sickle cell disease. American Journal of Hematology, 2004, 76, 126-133.	4.1	66

#	Article	IF	Citations
37	Overcoming barriers to cancer clinical trial accrual. Cancer, 2008, 112, 212-219.	4.1	64
38	Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia. PLoS ONE, 2014, 9, e101301.	2.5	64
39	A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal of Hematology and Oncology, 2013, 6, 17.	17.0	62
40	A comparison of multiplex suspension array largeâ€panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry Part B - Clinical Cytometry, 2009, 76B, 159-168.	1.5	59
41	Cancer Health Empowerment for Living without Pain (Ca-HELP): effects of a tailored education and coaching intervention on pain and impairment. Pain, 2011, 152, 1572-1582.	4.2	59
42	Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease*. International Journal of Laboratory Hematology, 2002, 24, 81-88.	0.2	58
43	The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease. Hematology, 2000, 5, 403-412.	1.5	57
44	Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. Journal of Rheumatology, 2005, 32, 2109-15.	2.0	56
45	Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Advances, 2017, 1, 1287-1295.	5.2	55
46	Physiologic concentrations of arginine vasopressin activate human platelets in vitro. British Journal of Haematology, 1996, 92, 968-972.	2.5	54
47	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Thrombosis and Haemostasis, 2017, 117, 2135-2145.	3.4	53
48	The sickle cell disease implementation consortium: Translating evidenceâ€based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395.	4.1	52
49	The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer, 2010, 116, 2596-2603.	4.1	49
50	Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia, 2001, 15, 208-216.	7.2	47
51	The incidence of cancer-associated thrombosis is increasing over time. Blood Advances, 2022, 6, 307-320.	5.2	46
52	Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. Journal of Clinical Oncology, 2014, 32, 1792-1796.	1.6	45
53	Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. British Journal of Haematology, 2017, 177, 791-799.	2.5	43
54	Usefulness of Optical Density Values From Heparinâ€“Platelet Factor 4 Antibody Testing and Probability Scoring Models to Diagnose Heparin-Induced Thrombocytopenia. American Journal of Clinical Pathology, 2007, 127, 429-433.	0.7	42

#	Article	IF	Citations
55	Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk?. Thrombosis Research, 2007, 120, S29-S40.	1.7	42
56	Sickle cell disease: an inherited thrombophilia. Hematology American Society of Hematology Education Program, 2016, 2016, 640-647.	2.5	42
57	Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thrombosis Research, 2010, 125, S96-S102.	1.7	40
58	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Instituteâ€designated cancer centers in California. Cancer, 2018, 124, 1938-1945.	4.1	40
59	Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. Journal of Cancer Survivorship, 2018, 12, 388-397.	2.9	39
60	Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential Therapeutics. Hematology/Oncology Clinics of North America, 2014, 28, 355-374.	2.2	38
61	Lymphoma and venous thromboembolism: influence on mortality. Thrombosis Research, 2014, 133, S23-S28.	1.7	38
62	Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. Cancer Causes and Control, 2018, 29, 551-561.	1.8	38
63	Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012â€“2013 in the United States. Pediatric Blood and Cancer, 2019, 66, e27426.	1.5	38
64	Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. American Journal of Hematology, 1997, 54, 225-232.	4.1	37
65	Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis. Journal of Oncology Practice, 2019, 15, e20-e29.	2.5	37
66	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. Journal of Hematology and Oncology, 2008, 1, 23.	17.0	35
67	Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. Blood, 2001, 97, 3401-3404.	1.4	34
68	Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology, 2011, 155, 263-267.	2.5	34
69	Platelet-erythrocyte adhesion in sickle cell disease. Journal of Investigative Medicine, 1999, 47, 121-7.	1.6	34
70	Risk assessment models for cancerâ€associated venous thromboembolism. Cancer, 2012, 118, 3468-3476.	4.1	33
71	Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study. Thrombosis Research, 2017, 153, 57-64.	1.7	33
72	Detection of plasmapheresis-induced platelet activation using monoclonal antibodies. Transfusion, 1992, 32, 534-540.	1.6	32

#	Article	IF	Citations
73	Prolonged circulation of activated platelets following plasmapheresis. Journal of Clinical Apheresis, 1994, 9, 10-16.	1.3	32
74	Comparison of real-time microvascular abnormalities in pediatric and adult sickle cell anemia patients. American Journal of Hematology, 2010, 85, 899-901.	4.1	32
75	Impact of Health Insurance on Stage at Cancer Diagnosis Among Adolescents and Young Adults. Journal of the National Cancer Institute, 2019, 111, 1152-1160.	6.3	32
76	Biomolecular markers of cancer-associated thromboembolism. Critical Reviews in Oncology/Hematology, 2013, 88, 19-29.	4.4	31
77	Removal by white cell-reduction filters of activated platelets expressing CD62. Transfusion, 1993, 33, 930-935.	1.6	29
78	How I diagnose and treat venous thromboembolism in sickle cell disease. Blood, 2018, 132, 1761-1769.	1.4	29
79	Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. Journal of Thrombosis and Haemostasis, 2010, 8, 987-997.	3.8	28
80	Effects of Poloxamer 188 Treatment on Sickle Cell Vaso-occlusive Crisis: Computer-Assisted Intravital Microscopy Study. Journal of Investigative Medicine, 2004, 52, 402-406.	1.6	25
81	A Phase 3 Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle ÃŸ0-Thalassemia. Blood, 2014, 124, 86-86.	1.4	25
82	Desmopressin stimulates the expression of P-selectin on human platelets in vitro. Translational Research, 1995, 126, 401-9.	2.3	25
83	Patientâ€reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. American Journal of Hematology, 2020, 95, 1066-1074.	4.1	24
84	Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes. Thrombosis Research, 2016, 140, S132-S141.	1.7	23
85	Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in California. Blood, 2016, 128, 2489-2489.	1.4	23
86	Multiplexed measurements of immunomodulator levels in peripheral blood of healthy subjects: Effects of analytical variables based on anticoagulants, age, and gender. , 2014, 86, 426-435.		22
87	Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer Journal, 2017, 7, e605-e605.	6.2	22
88	The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy. Hematology, 2001, 5, 403-412.	1.5	22
89	Platelet activation during dobutamine stress echocardiography. American Heart Journal, 1998, 135, 888-900.	2.7	21
90	Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecologic Oncology, 2006, 102, 98-102.	1.4	21

#	Article	IF	Citations
91	The Felty Syndrome and G-CSF-Associated Thrombocytopenia and Severe Anemia. Annals of Internal Medicine, 1993, 118, 318.	3.9	20
92	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. Journal of the National Cancer Institute, 2019, 111, 78-85.	6.3	20
93	Bleeding in patients with sickle cell disease: a population-based study. Blood Advances, 2020, 4, 793-802.	5.2	20
94	High incidence of venous thromboembolism recurrence in patients with sickle cell disease. American Journal of Hematology, 2019, 94, 862-870.	4.1	19
95	Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia. Blood Cells, Molecules, and Diseases, 2020, 81, 102388.	1.4	19
96	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. JMIR Research Protocols, 2020, 9, e16319.	1.0	19
97	Cancer Health Empowerment for Living without Pain (Ca-HELP): study design and rationale for a tailored education and coaching intervention to enhance care of cancer-related pain. BMC Cancer, 2009, 9, 319.	2.6	18
98	Vasopressin and platelets: a concise review. Platelets, 1997, 8, 15-22.	2.3	16
99	Emergency department use by recently diagnosed cancer patients in California. Journal of Community and Supportive Oncology, 2017, 15, 95-102.	0.1	16
100	Emergency Department Sickle Cell Assessment of Needs and Strengths (EDâ€SCANS), a Focus Group and Decision Support Tool Development Project. Academic Emergency Medicine, 2010, 17, 848-858.	1.8	15
101	Incidence of Venous Thromboembolism in Patients with Acute Leukemia.. Blood, 2006, 108, 1497-1497.	1.4	15
102	Safety of light emitting diodeâ€red light on human skin: Two randomized controlled trials. Journal of Biophotonics, 2020, 13, e201960014.	2.3	14
103	Racial disparities in cancer-associated thrombosis. Blood Advances, 2022, 6, 3167-3177.	5.2	14
104	Exchange Transfusion Therapy and Its Effects on Real-time Microcirculation in Pediatric Sickle Cell Anemia Patients. Journal of Pediatric Hematology/Oncology, 2012, 34, 169-174.	0.6	13
105	Impact of insurance type and timing of Medicaid enrollment on survival among adolescents and young adults with cancer. Pediatric Blood and Cancer, 2020, 67, e28498.	1.5	13
106	Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia. JCO Oncology Practice, 2020, 16, e1120-e1133.	2.9	13
107	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). Blood, 2018, 132, LBA-1-LBA-1.	1.4	12
108	Radioimmunotherapy. BioDrugs, 2001, 15, 151-162.	4.6	11

#	Article	IF	Citations
109	Vena Cava Filter Use in Cancer Patients with Acute Venous Thromboembolism in California. Thrombosis Research, 2015, 135, 809-815.	1.7	11
110	Complications and early mortality in patients with acute promyelocytic leukemia treated in California. American Journal of Hematology, 2018, 93, E370-E372.	4.1	11
111	A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. American Journal of Hematology, 2019, 94, E291-E294.	4.1	11
112	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer Journal, 2021, 11, 5.	6.2	11
113	Early manifestation of thrombotic thrombocytopenic purpura. American Journal of Medicine, 1993, 95, 544-545.	1.5	10
114	Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant. Annals of Hematology, 2002, 81, 108-110.	1.8	10
115	Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 314-321.	0.3	10
116	Detecting opioid metabolites in exhaled breath condensate (EBC). Journal of Breath Research, 2019, 13, 046014.	3.0	10
117	Chronic medical conditions and late effects following nonâ€Hodgkin lymphoma in HIVâ€uninfected and HIVâ€infected adolescents and young adults: a populationâ€based study. British Journal of Haematology, 2020, 190, 371-384.	2.5	10
118	Urbanâ€“Rural Variations in Quality of Care Among Patients With Cancer in California. American Journal of Preventive Medicine, 2021, 61, e279-e288.	3.0	10
119	Jumpstarting Academic Careers with a Novel Intern Research Rotation: the AIMS Rotation. American Journal of Medicine, 2009, 122, 1061-1066.	1.5	9
120	Disparities in the Occurrence of Late Effects following Treatment among Adolescent and Young Adult Melanoma Survivors. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2195-2202.	2.5	9
121	Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136, 18-19.	1.4	9
122	Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Advances, 2022, 6, 1212-1221.	5.2	9
123	Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. JCO Oncology Practice, 2022, 18, e586-e599.	2.9	9
124	Acute myocardial infarction in hemoglobin SC disease. Annals of Hematology, 2004, 83, 622-4.	1.8	8
125	Best practices for transfusion for patients with sickle cell disease. Hematology Reports, 2009, 1, 22.	0.8	8
126	Adverse Impact of Venous Thromboembolism on Patients with Cancer. Seminars in Thrombosis and Hemostasis, 2014, 40, 313-318.	2.7	8

#	Article	IF	Citations
127	Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. Journal of Oncology Practice, 2019, 15, e316-e327.	2.5	8
128	Episodes of High Emergency Department Utilization Among a Cohort of Persons Living with Sickle Cell Disease. Blood, 2018, 132, 159-159.	1.4	8
129	Filgrastim Treatment of Acute Myelogenous Leukemia (M7) Relapse after Allogeneic Peripheral Stem Cell Transplantation Resulting in Both Graft-versus-Leukemia Effect with Cytogenetic Remission and Chronic Graft-versus-Host Disease Manifesting as Polyserositis and Subsequent Bronchiolitis Obliterans with Organizing Pneumonia. International Journal of Hematology, 2002, 76, 360-364.	1.6	7
130	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy. Blood Cells, Molecules, and Diseases, 2016, 60, 44-48.	1.4	7
131	Biomarkers of Cancer-Associated Thromboembolism. Cancer Treatment and Research, 2019, 179, 69-85.	0.5	7
132	Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients. British Journal of Haematology, 2020, 190, 450-457.	2.5	7
133	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	1.4	7
134	Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers. Thrombosis and Haemostasis, 2022, 122, 1407-1414.	3.4	7
135	The Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS). Advanced Emergency Nursing Journal, 2013, 35, 143-153.	0.5	6
136	GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease. Blood, 2010, 116, 1632-1632.	1.4	6
137	Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial. Journal of Clinical Oncology, 2004, 22, 2554-2554.	1.6	6
138	Treatment at Specialized Cancer Centers Is Associated with Improved Survival in Adolescent and Young Adults with Soft Tissue Sarcoma. Journal of Adolescent and Young Adult Oncology, 2022, 11, 370-378.	1.3	6
139	Cancer associated venous thromboembolism: incidence and impact on survival. Thrombosis Research, 2018, 164, S178-S179.	1.7	5
140	Cancer specific survival in patients with sickle cell disease. British Journal of Haematology, 2019, 185, 128-132.	2.5	5
141	Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality. TH Open, 2020, 04, e309-e317.	1.4	5
142	A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease. Blood, 2011, 118, 847-847.	1.4	5
143	The Incidence and Timing of Unprovoked Venous Thromboembolism Prior to the Diagnosis of Common Cancers.. Blood, 2004, 104, 2582-2582.	1.4	5
144	COVID-19 and venous thromboembolism risk in patients with sickle cell disease. Blood Advances, 2022, 6, 4408-4412.	5.2	5

#	Article	IF	Citations
145	Clonal remission in aplastic anemia after treatment with antithymocyte globulin. American Journal of Hematology, 1992, 40, 229-231.	4.1	4
146	A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. Trials, 2016, 17, 385.	1.6	4
147	High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. Leukemia and Lymphoma, 2020, 61, 2605-2613.	1.3	4
148	Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcomaâ€"A populationâ€based study. Pediatric Blood and Cancer, 2021, 68, e28998.	1.5	4
149	Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 Study. Blood, 2010, 116, 262-262.	1.4	4
150	Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. Blood, 2014, 124, 2704-2704.	1.4	4
151	Upper extremity deep venous thrombosis in 10 common malignancies: Analysis of incidence, risk factors, and effect on mortality from the California Cancer Registry.. Journal of Clinical Oncology, 2019, 37, e18190-e18190.	1.6	4
152	Stage at diagnosis and survival among adolescents and young adults with lymphomas following the Affordable Care Act implementation in California. International Journal of Cancer, 2021, , .	5.1	4
153	UC Davis CTSA: Coming of Age. Clinical and Translational Science, 2009, 2, 98-101.	3.1	3
154	Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070. Blood, 2011, 118, 851-851.	1.4	3
155	Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM). Blood, 2016, 128, 846-846.	1.4	3
156	Incidence of Venous Thromboembolism and Impact on Mortality in Patients with Primary CNS Lymphoma: A Population Based Study. Blood, 2017, 130, 754-754.	1.4	3
157	Incidence of Bleeding in Patients with Sickle Cell Disease: A Population Based Study. Blood, 2018, 132, 10-10.	1.4	3
158	Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. Blood, 2020, 136, 20-21.	1.4	3
159	PO-95 Venous thromboembolism (VTE) is associated with recurrent cancer in patients with initially non-metastatic breast, lung, and colon cancer. Thrombosis Research, 2007, 120, S175.	1.7	2
160	Mightier than the sickle cell. Blood, 2010, 116, 1633-1633.	1.4	2
161	Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California. Leukemia and Lymphoma, 2018, 59, 2482-2484.	1.3	2
162	Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 498.e1-498.e7.	1.6	2

#	Article	IF	Citations
163	Early mortality and survival improvements for adolescents and young adults with acute promyelocytic leukemia in California: an updated analysis. Haematologica, 2022, 107, 733-736.	3.5	2
164	Cause of Death among Patients with Local or Regional Stage Cancer of the Breast, Colon and Lung Who Develop Venous Thromboembolism (VTE).. Blood, 2006, 108, 1501-1501.	1.4	2
165	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 â€“ A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood, 2013, 122, 2206-2206.	1.4	2
166	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
167	Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study. Blood, 2016, 128, 3982-3982.	1.4	2
168	The reply:. American Journal of Medicine, 2001, 110, 156-157.	1.5	1
169	COVID-19 Testing for Underserved and Vulnerable Populations: The NIH Rapid Acceleration Of Diagnostics (RADx) Initiative, Experiences from the field. ISEE Conference Abstracts, 2021, 2021, .	0.0	1
170	Building an institutional K awardee program at UC Davis through utilization of CTSA resources. Journal of Clinical and Translational Science, 2021, 5, e171.	0.6	1
171	Splenectomy and the Incidence of Venous Thromboembolism and Sepsis In Patients with Immune Thrombocytopenia,. Blood, 2011, 118, 3284-3284.	1.4	1
172	Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State. Blood, 2012, 120, 87-87.	1.4	1
173	Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 839-839.	1.4	1
174	Pregnancy Outcomes in Women with Sickle Cell Disease in California: A Retrospective Cohort Study. Blood, 2021, 138, 489-489.	1.4	1
175	Second Primary Malignancy Risk Among HIV-Uninfected and HIV-Infected Survivors of Hodgkin Lymphoma: A 30-Year Follow-up Population-Based Study. Blood, 2020, 136, 15-17.	1.4	1
176	Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California. Blood, 2020, 136, 4-5.	1.4	1
177	Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors. Leukemia and Lymphoma, 2022, , 1-11.	1.3	1
178	A method to identify California's sickle-cell disease population and its linkage to the California Cancer Registry. Journal of Registry Management, 2012, 39, 53-61.	0.1	1
179	Assessment of bleeding risk in the patient with no history of hemostatic problems. , 0, , 219-229.		0
180	The US Initiative: Clinical and Translational Science Awards Â– The UC Davis Perspective. Translational Research in Biomedicine, 2012, , 18-28.	0.4	0

#	Article	IF	Citations
181	Use of vena cava filters in cancer patients in California. Thrombosis Research, 2012, 129, S161-S162.	1.7	0
182	Severity-of-illness in cancer patients contributes to the risk of hospital-acquired venous thromboembolism (VTE), but not post-discharge VTE. Thrombosis Research, 2012, 129, S166-S167.	1.7	0
183	MP15-06 ASSESSMENT OF QUALITY OF CARE IN NON-MUSCLE INVASIVE BLADDER CANCER: UPTAKE OF RE-RESECTION FOR HIGH GRADE OR T1 BLADDER TUMORS IN CALIFORNIA. Journal of Urology, 2017, 197, .	0.4	0
184	PD19-04 IMMEDIATE INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER TUMORS IN CALIFORNIA: AN UNDERUTILIZED PRACTICE AND ITS IMPACT ON RECURRENCE. Journal of Urology, 2017, 197, .	0.4	0
185	Incidence of symptomatic venous thrombosis in cervical and vulvo-vaginal carcinoma treated with concurrent chemoradiation, erythropoietin, and coumadin. Journal of Clinical Oncology, 2004, 22, 8101-8101.	1.6	0
186	Awareness among oncology providers and financial counselors of a California law requiring third-party payer coverage of cancer clinical Trial (CCT) Costs. Journal of Clinical Oncology, 2005, 23, 6111-6111.	1.6	0
187	Venous thromboembolism in 9,489 patients with glioma. Journal of Clinical Oncology, 2006, 24, 1538-1538.	1.6	0
188	Impact of a mass media campaign (MMC) on awareness of and willingness to participate in cancer clinical trials (CCT): Results from 2,269 survey respondents. Journal of Clinical Oncology, 2006, 24, 6012-6012.	1.6	0
189	Utility of Optical Density Values from Heparin-Platelet Factor 4 Antibody Testing and Probability Scoring Models To Diagnose Patients with Heparin Induced Thrombocytopenia.. Blood, 2006, 108, 1475-1475.	1.4	0
190	A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.. Blood, 2007, 110, 3216-3216.	1.4	0
191	Positron emission tomography (PET) and improved survival in non-small cell lung cancer (NSCLC) patients: The Will Rogers Phenomenon revisited. Journal of Clinical Oncology, 2008, 26, 11038-11038.	1.6	0
192	Identification of Novel Peptide Ligands Targeting Î±4Î²1 Integrins on Patient Lymphoma Cells. Blood, 2010, 116, 4854-4854.	1.4	0
193	Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes In Sickle Cell Patients Not In Crisis. Blood, 2010, 116, 2672-2672.	1.4	0
194	Incidence and Risk Factors for Intracranial Hemorrhage in Californians with Immune Thrombocytopenia. Blood, 2011, 118, 1161-1161.	1.4	0
195	Increased Incidence of Hematological Malignancies Among Californians with Sickle Cell Disease. Blood, 2011, 118, 1073-1073.	1.4	0
196	Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease. Blood, 2011, 118, 2127-2127.	1.4	0
197	Increased Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor (sLOX-1) and Increased Endothelial Cell Expression of LOX-1 in Sickle Cell Disease (SCD): A Novel Marker for SCD Vasculopathy?. Blood, 2012, 120, 246-246.	1.4	0
198	Monocyte Chemotactic Protein-1 Is Associated with Microvascular Abnormalities and Serum Ferritin Concentrations in Sickle Cell Disease Patients. Blood, 2012, 120, 3255-3255.	1.4	0

#	Article	IF	Citations
199	Pharmacologic Thromboprophylaxis Is Frequently Prescribed In Hospitalized Cancer Patients At Academic Medical Centers: A Prospective, Cross-Sectional, Multi-Center Study. Blood, 2013, 122, 2374-2374.	1.4	0
200	Predictors Of Vena Cava Filter Use For Venous Thromboembolism In Cancer Patients. Blood, 2013, 122, 935-935.	1.4	0
201	Outcomes After Vena Cava Filter Placement In Cancer Patients Hospitalized For Acute Venous Thromboembolism. Blood, 2013, 122, 936-936.	1.4	0
202	A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab Era. Blood, 2014, 124, 2609-2609.	1.4	0
203	Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact. Blood, 2015, 126, 1305-1305.	1.4	0
204	The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment. Blood, 2015, 126, 1991-1991.	1.4	0
205	Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time. Blood, 2016, 128, 2375-2375.	1.4	0
206	Sociodemographic Factors Predict Medical Conditions Among Five-Year Survivors of Adolescent and Young Adult Hodgkin Lymphoma. Blood, 2016, 128, 693-693.	1.4	0
207	Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California. Blood, 2016, 128, 391-391.	1.4	0
208	Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). Blood, 2018, 132, 985-985.	1.4	0
209	Inpatients Costs of Cancer Treatment Among Children and Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated at Specialized Cancer Centers in California. Blood, 2018, 132, 324-324.	1.4	0
210	Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time. Blood, 2018, 132, 3598-3598.	1.4	0
211	Worse Outcomes Associated with Public Insurance in AYAs with Leukemia and Lymphoma. Blood, 2018, 132, 977-977.	1.4	0
212	Incidence and Outcomes Associated with Distal Deep Vein Thrombosis in 760,344 Patients with 13 Common Malignancies. Blood, 2018, 132, 2526-2526.	1.4	0
213	Worse outcomes associated with public insurance at sarcoma diagnosis in adolescent and young adults (AYAs).. Journal of Clinical Oncology, 2019, 37, e18143-e18143.	1.6	0
214	Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Non-Hodgkin's Lymphoma: Analysis of the California Cancer Registry. Blood, 2019, 134, 932-932.	1.4	0
215	Racial/Ethnic Disparities in Cancer-Associated Thrombosis: A Population-Based Study. Blood, 2020, 136, 53-55.	1.4	0
216	Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study. Blood, 2020, 136, 47-48.	1.4	0

#	Article	IF	Citations
217	Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults. Current Epidemiology Reports, 0, , 1.	2.4	0